The Third Xiangya Hospital of Central South University
Welcome,         Profile    Billing    Logout  
 300 Trials 
1341 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Li, Ying
STRATEGY, NCT05310968: Study on Tirofiban With Aspirin in the Treatment of Acute Penetrating Artery Territory Infarction

Recruiting
4
970
RoW
Tirofiban hydrochloride sodium chloride injection, Tirofiban hydrochloride sodium chloride injection placebo, Aspirin
Beijing Tiantan Hospital, GrandPharma (China) Co., Ltd.
Branch Atheromatous Disease
06/24
09/24
NCT04624854: Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD)

Active, not recruiting
4
8250
RoW
Clopidogrel and Aspirin dual-antiplatelet therapy, Aspirin monotherapy
Harbin Medical University, Chinese Society of Cardiology, Lepu Medical Technology (Beijing) Co., Ltd.
Coronary Artery Disease, Myocardial Ischemia, Acute Coronary Syndrome, Heart Diseases, Syndrome Heart Disease, Cardiovascular Diseases, Arteriosclerosis, Arterial Occlusive Diseases, Coronary Disease, Vascular Diseases
04/25
04/25
SHINY, NCT06157502: Shuxuening Injection in the Treatment With Intravenous Thrombolysis in Patients With Ischemic Stroke

Recruiting
3
1380
RoW
Shuxuening Injection, Placebo
Beijing Tiantan Hospital
Ischemic Stroke, Acute
06/25
12/26
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

Recruiting
3
12500
Europe, Canada, Japan, US, RoW
Lepodisiran Sodium, LY3819469, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
03/29
03/29
TAPIS, NCT06316570: Ticagrelor With Aspirin Dual Antiplatelet Therapy Combined With Intravenous Thrombolysis for Ischemic Stroke

Recruiting
3
1380
RoW
Early Dual Antiplatelet Therapy, Ticagrelor and Aspirin, Placebo, Placebo of Ticagrelor and Aspirin
Beijing Tiantan Hospital
Ischemic Stroke, Acute
12/25
12/26
NCT06775860: ICP-332 in Subjects with Moderate to Severe Atopic Dermatitis

Recruiting
3
552
RoW
ICP-332 Tablets, ICP-332 Placebo Tablets
Beijing InnoCare Pharma Tech Co., Ltd.
Atopic Dermatitis
11/26
12/26
NCT06631170: Efficacy and Safety of Roflumilast Cream in Subjects with Atopic Dermatitis

Recruiting
3
351
RoW
Roflumilast Cream 0.15%, Vehicle cream
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Atopic Dermatitis (AD)
08/25
08/25
TQH3906-II-01, NCT06542614: Treatment of Moderate to Severe Plaque Psoriasis

Recruiting
2
120
RoW
TQH3906 capsules, Placebo of TQH3906 capsules
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Plaque Psoriasis
01/25
09/25
TQB2928-Ib-01, NCT06008405: Clinical Trial Evaluating the Safety of the TQB2928 Injection Combination Therapy

Recruiting
1
48
RoW
TQB2928 Injection + Azacitidine for injection
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Acute Myeloid Leukemia, Myelodysplastic Syndromes
05/25
05/25
NCT02946528: Urgent-start Peritoneal Dialysis in ESRD Patients:A Multi-center Study

Completed
N/A
116
RoW
urgent-start peritoneal dialysis catheter, central venous catheter
RenJi Hospital, Ruijin Hospital, Xin Hua Hospital, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Changhai Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai Tong Ren Hospital, Shanghai Jiading District Central Hospital, Shanghai Songjiang District Central Hospital, The Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine, Shanghai Punan Hospital
End-Stage Renal Disease
11/21
11/21
NCT04714918: Chinese CKD-MBD Prevalence Survey (CRISS-MBD)

Recruiting
N/A
10254
RoW
Limeng Chen
Chronic Kidney Diseases, Chronic Kidney Disease-Mineral and Bone Disorder
12/24
12/24
NCT06142201: A Real-World Study of JT001 for COVID-19

Active, not recruiting
N/A
7656
RoW
JT001, DeuremidevirHydrobromideTablets
Shanghai Vinnerna Biosciences Co., Ltd.
COVID-19
11/24
12/24
CVBT, NCT04500041: Casting Vs Bracing for Idiopathic Early-Onset Scoliosis

Active, not recruiting
N/A
71
Europe, US, RoW
Casting, Bracing
University of Iowa, Orthopedic Research and Education Foundation, Pediatric Spine Study Group
Scoliosis Idiopathic, Early-Onset Scoliosis Deformity of Spine
01/26
01/26
FACTS, NCT04250415: Multi-Center Adolescent Clavicle Fracture Trial: Operative Vs. Non-Operative Treatment

Recruiting
N/A
250
US
Surgery
Boston Children's Hospital, Rady Children's Hospital, San Diego, University of Michigan, Texas Scottish Rite Hospital for Children, Washington University School of Medicine, Campbell Clinic, University of California, San Francisco, Children's Healthcare of Atlanta
Clavicle Fracture
06/25
06/26
NCT05540808: The Value of Full-targeted Pathogen Capture Metagenomics Next Generation Sequencing in Etiological Diagnosis of Sepsis

Not yet recruiting
N/A
86
NA
Shenzhen Second People's Hospital
Sepsis, Severe
07/24
06/25
TESTING-ON, NCT05434325: TESTING -ON Post-Trial ObservatioNal Cohort Study

Recruiting
N/A
366
Canada, RoW
The George Institute, Peking University Institute of Nephrology
IgA Nephropathy, ESRD, Glomerulonephritis, Kidney Diseases
07/27
07/27
NCT05756959: Myopia Control Combined PBM With Myopic Defocus Lens in Children

Recruiting
N/A
304
RoW
PBM, Low lever light therapy; low intensity red light therapy; low lever laser therapy; repeated red light therapy, Peripheral defocus spectacles, Myopic defocus spectacles for myopia control, Single vision spectacles, single vision glasseses for myopia correction lenses
Beijing Airdoc Technology Co., Ltd., The First People's Hospital of Xuzhou
Myopia, Progressive
08/27
12/27
NCT06039917: Effect of the Automatic Surveillance System on Surveillance Rate of Patients with Gastric Premalignant Lesions

Recruiting
N/A
1460
RoW
AI based automatic surveillance (AS) system (ENDOANGEL-AS), Manually remind the patients
Renmin Hospital of Wuhan University, Shanghai Pudong Hospital, The Eighth Hospital of Wuhan, Jinjiang Municipal Hospital, Shanghai Sixth People's Hospital Fujian Campus
Artificial Intelligence, Surveillance
12/28
12/29
NCT04960371: Effects of Anxiety on Coronary Microcirculatory Function in Hypertensive Patients

Recruiting
N/A
200
RoW
coronary flow reserve (CFR)
Peking University Third Hospital
Coronary Microvascular Disease, Anxiety State
12/22
12/22
Zhang, Hao
STRATEGY, NCT05310968: Study on Tirofiban With Aspirin in the Treatment of Acute Penetrating Artery Territory Infarction

Recruiting
4
970
RoW
Tirofiban hydrochloride sodium chloride injection, Tirofiban hydrochloride sodium chloride injection placebo, Aspirin
Beijing Tiantan Hospital, GrandPharma (China) Co., Ltd.
Branch Atheromatous Disease
06/24
09/24
NCT06597201: Evaluate the Efficacy and Safety of Amino Acid (15) Peritoneal Dialysis Solution in Peritoneal Dialysis Patients with Malnutrition.

Recruiting
4
400
RoW
amino acid (15) peritoneal dialysis solution, glucose peritoneal dialysis solution
Chengdu Qingshan Likang Pharmaceutical Co., Ltd
End Stage Renal Disease (ESRD)
06/25
06/25
NCT04381143: ASPIrin in Reducing Events in Dialysis ( ASPIRED )

Recruiting
4
9000
RoW
Aspirin 100 mg Oral Tablet, Matching Placebo
Guangdong Provincial People's Hospital, The George Institute
CKD (Chronic Kidney Disease) Stage 5D
09/26
12/26
ALIGN, NCT04573478: Atrasentan in Patients With IgA Nephropathy

Active, not recruiting
3
404
Europe, Canada, Japan, US, RoW
Atrasentan, CHK-01, Atrasentan Hydrochloride, ABT-627, Placebo
Chinook Therapeutics, Inc.
IgA Nephropathy, Immunoglobulin A Nephropathy
12/26
12/26
NCT06419621: PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic Triple-negative Breast Cancer

Recruiting
3
360
RoW
PM8002, Nab-Paclitaxel, Placebo
Biotheus Inc.
Triple Negative Breast Cancer(TNBC)
07/27
07/28
NCT01954992: Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer

Recruiting
3
480
US
Glufosfamide, Fluorouracil, 5-FU
Eleison Pharmaceuticals LLC.
Metastatic Pancreatic Adenocarcinoma
06/26
12/26
PALIZADE, NCT05781750: A Study of Zetomipzomib (KZR-616) in Patients With Active Lupus Nephritis

Suspended
2
279
Europe, US, RoW
zetomipzomib, KZR-616, placebo, matching placebo
Kezar Life Sciences, Inc.
Lupus Nephritis
05/26
07/26
NCT04476485: Sj-subway, a Predictor for the Recurrence of High-risk Hormone Receptor-positive Breast That is Sensitive to Extended Endocrine Therapy

Recruiting
N/A
1000
RoW
endocrine therapy
Shengjing Hospital
Breast Cancer
12/21
12/26
NCT05296369: Folic Acid Interferes With Radiation Esophagitis

Recruiting
N/A
90
RoW
Folic acid
Guizhou Medical University
Lung Cancer
05/23
05/23
LOFTY, NCT06577792: Lobectomy-First vs. Lymphadenectomy-First for Operable NSCLC

Recruiting
N/A
620
RoW
Lobectomy-First, Lymphadenectomy-First
Sun Yat-sen University, Tianjin Medical University Cancer Institute and Hospital, RenJi Hospital, Sixth Affiliated Hospital, Sun Yat-sen University, First Affiliated Hospital of Jinan University, The First Affiliated Hospital with Nanjing Medical University, Hebei Medical University Fourth Hospital, Shanghai Changzheng Hospital, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Suining Central Hospital, Ningbo Medical Center Lihuili Hospital, Shanxi Provincial Cancer Hospital, The Affiliated Hospital of Xuzhou Medical University, The General Hospital of Eastern Theater Command, First Affiliated Hospital, Sun Yat-Sen University, Guangdong Provincial People's Hospital, Fujian Medical University Union Hospital, First Affiliated Hospital of Kunming Medical University, Fujian Provincial Hospital, Tianjin Chest Hospital, Sichuan Cancer Hospital and Research Institute, Shenzhen People's Hospital, Tang-Du Hospital, Shandong Provincial Hospital, Gansu Provincial Hospital, Wuhan Union Hospital, China, Wuhan TongJi Hospital, The Affiliated Hospital of Qingdao University, West China Hospital, The First Affiliated Hospital of Nanchang University, Jiangsu Cancer Institute & Hospital, Dongguan People's Hospital, First People's Hospital of Foshan
Non Small Cell Lung Cancer
12/24
12/29
NCT05042531: Clinical Research for Azacitidine Combined With Low-dose Dasatinib in Maintenance Therapy of Acute Myeloid Leukemia

Recruiting
N/A
30
RoW
Azacitidine, Dasatinib
LanZhou University, Beijing Health Alliance Charitable Foundation
Acute Myeloid Leukemia
09/23
12/23
NCT05735262: pBFS Guided Precision Neuromodulation Treatment for ASD

Recruiting
N/A
100
RoW
active iTBS, sham iTBS
Changping Laboratory, China Rehabilitation Research Center
Autism Spectrum Disorder
03/24
01/25
NCT05842304: Individualized Precision rTMS for Language Recovery in Patients After Ischemic Stroke: a Multi-center RCT

Recruiting
N/A
180
RoW
active cTBS, sham cTBS
Changping Laboratory
Stroke, Ischemic, Aphasia
05/25
05/26
NCT05475756: Safety and Efficacy of Intrauterine Biological Barrier on Postoperative Adhesion After Hysteroscopic Adhesiolysis

Recruiting
N/A
264
RoW
Intrauterine Biological Barrier, Intrauterine Adhesion Barrier Gel
Beijing Tiantan Hospital, Zhangzhou Municipal Hospital of Fujian Province, Guangzhou First People's Hospital, Tang-Du Hospital, Suzhou Municipal Hospital, Anhui Provincial Hospital
Intrauterine Adhesion
05/24
05/25
NCT06499974: POASAC Study (Preoperative Anemia Severity and Classification Study)

Recruiting
N/A
1000
RoW
Peking Union Medical College Hospital
Anemia
12/25
12/26
NCT05890846: Precision TMS Treatment Guided by Personalized Brain Functional Sectors (pBFS) for ASD

Recruiting
N/A
66
RoW
active iTBS, sham iTBS, traditional 1on1 course
Changping Laboratory, Henan Provincial People's Hospital, China Rehabilitation Research Center
Autism Spectrum Disorder
09/24
09/25
INFINITE, NCT04328662: A Study of Ninlaro in Real World Clinical Practice in China

Active, not recruiting
N/A
482
RoW
Takeda
Multiple Myeloma, Neoplasms, Plasma Cell
09/25
09/25
NCT05091229: A Blood Test to Diagnose Kawasaki Disease

Not yet recruiting
N/A
800
NA
HBI Solutions Inc., Shanghai Children's Medical Center, mProbe Inc.
Kawasaki Disease
12/24
12/24
PREACT-AF, NCT06728826: Prevention of Atrial Fibrillation After Cardiac Surgery by Posterior Pericardiotomy

Not yet recruiting
N/A
648
RoW
Posterior Pericardiotomy
Changhai Hospital
Atrial Fibrillation (AF), Cardiac Events
12/25
06/26
POMLDYY, NCT05378971: Clinical Research of Pomalidomide Maintenance Therapy for Primary Multiple Myeloma

Recruiting
N/A
15
RoW
Pomalidomide, Pomalyst
LanZhou University, Beijing Health Alliance Charitable Foundation
Multiple Myeloma
05/25
05/25
NCT05953415: pBFS-guided iTBS Over the Left DLPFC for Chronic PSCI

Recruiting
N/A
60
RoW
active iTBS, sham iTBS
Changping Laboratory, China Rehabilitation Research Center
Chronic Stroke, Cognitive Impairment
07/25
10/25
Badve, Sunil
TRACK, NCT03969953 / 2020-000334-17: Treatment of Cardiovascular Disease With Low Dose Rivaroxaban in Advanced Chronic Kidney Disease

Calendar Jan 2025 - Dec 2025: From TRACK trial for cardiovascular disease in chronic kidney disease
Recruiting
3
2000
Europe, Canada, RoW
Rivaroxaban 2.5 Mg Oral Tablet, Xarelto, Placebo
The George Institute, George Clinical Pty Ltd, Bayer, Centre Hospitalier Régional Universitaire de Nancy, King Abdullah International Medical Research Center
Chronic Kidney Diseases, Dialysis-dependent Kidney Failure, Cardiovascular Disease
06/27
12/27
REGEN-006, NCT05099770: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease

Recruiting
3
685
Europe, Canada, US, RoW
Renal Autologous Cell Therapy (REACT), Sham Comparator
Prokidney, Iqvia Pty Ltd, PPD
Type 2 Diabetes Mellitus, Chronic Kidney Diseases
02/27
02/27
CAPTIVATE, NCT06058585: The Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect

Recruiting
3
1000
RoW
Finerenone, BAY94-8862, Placebo Finerenone
The George Institute
Chronic Kidney Diseases
08/28
12/28
PALIZADE, NCT05781750: A Study of Zetomipzomib (KZR-616) in Patients With Active Lupus Nephritis

Suspended
2
279
Europe, US, RoW
zetomipzomib, KZR-616, placebo, matching placebo
Kezar Life Sciences, Inc.
Lupus Nephritis
05/26
07/26
PHOSPHATE, NCT03573089: Pragmatic Randomised Trial of High Or Standard PHosphAte Targets in End-stage Kidney Disease

Recruiting
N/A
3600
Europe, Canada, RoW
Liberal phosphate target, Intensive phosphate target
The University of Queensland, National Health and Medical Research Council, Australia, Applied Health Research Centre, Cambridge University Hospitals NHS Foundation Trust, University of Otago
Kidney Failure, Chronic, Hyperphosphatemia
12/27
12/28
Investigator, Principal
OCEAN, NCT04986982 / 2020-001175-32: OpiCapone Effect on Motor Fluctuations and pAiN

Completed
4
144
Europe
Opicapone 50 mg, BIA 9-1067, Placebo
Bial - Portela C S.A., Bial - Portela & Ca, S.A.
Parkinson Disease
02/24
02/24
NCT04248205: Ketamine for Post-operative Analgesia in Hemorrhoidectomy

Recruiting
4
100
US
Ketamine
University of Oklahoma
Hemorrhoids
01/25
07/25
NCT05400369: A Study to Evaluate the Efficacy and Safety of Sitafloxacin in Adult Subjects With Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Completed
4
140
RoW
Sitafloxacin, Gracevit, Moxifloxacin Hydrochloride, Avelox
Daiichi Sankyo
COPD Exacerbation Acute
09/24
09/24
TrEAT_TD2, NCT05677282: Single Dose Antibiotic Treatment of Acute Watery Diarrhea, Rifaximin Versus Azithromycin, with Loperamide Adjunct

Recruiting
4
150
RoW
Rifaximin 550 MG, Azithromycin 500 MG, Loperamide
Henry M. Jackson Foundation for the Advancement of Military Medicine, Infectious Diseases Clinical Research Program, Uniformed Services University of the Health Sciences
Diarrhoea;Acute, Diarrhea Travelers
09/25
12/25
NCT06397781: Effect of S. Aureus Skin Decolonization on Disease Severity in Atopic Dermatitis Patients

Not yet recruiting
4
100
US
Skin Cleanser Combination No.1
Boston Children's Hospital
Atopic Dermatitis
12/28
12/28
NCT06793358: Use of Remimazolam and Fentanyl for Procedural Sedation in Patients Undergoing Dental Extraction

Not yet recruiting
4
40
US
fentanyl and Remimazolam
Indiana University, Indiana University Health
Dental Extraction
01/26
03/26
POUR, NCT04994431: Post-Operative Urinary Retention () in Thoracic Surgery Patients Receiving Prophylactic Tamsulosin

Terminated
4
109
US
Tamsulosin Hydrochloride
University of Massachusetts, Worcester, UMass Memorial Health Care
Thoracic Diseases, Urinary Retention
10/23
10/23
NCT02932410 / 2016-001062-28: A Study to Assess Whether Macitentan Delays Disease Progression in Children With Pulmonary Arterial Hypertension (PAH)

Active, not recruiting
3
165
Europe, Canada, US, RoW
Macitentan, ACT-064992, Standard-of-care
Actelion
Pulmonary Arterial Hypertension
08/24
07/25
TROPION-LUNG01, NCT04656652 / 2020-004643-80: Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations

Hourglass Jul 2023 - Dec 2023 : Acceptance of regulatory submission for 2L+ NSCLC with or without actionable genomic alterations (based on TROPION-Lung01 trial)
Apr 2023 - Jun 2023: Topline results from TROPION-LUNG01 trial for metastatic NSCLC
Active, not recruiting
3
590
Europe, Canada, Japan, US, RoW
DS-1062a, Datopotamab deruxtecan (Dato-DXd), Docetaxel
Daiichi Sankyo, AstraZeneca
Non-small Cell Lung Cancer
05/24
06/25
IDeate-Lung02, NCT06203210: A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

Recruiting
3
540
Europe, Canada, Japan, US, RoW
Ifinatamab deruxtecan, I-DXd, Topotecan, Amrubicin, Lurbinectedin
Daiichi Sankyo, Merck Sharp & Dohme LLC
Small Cell Lung Cancer
04/27
02/29
TNX-N, NCT03503136: Nedaplatin Versus Cisplatin and Capecitabine Versus Fluorouracil in IC + CCRT for Locoregionally Advanced NPC

Not yet recruiting
3
632
RoW
docetaxel, nedaplatin, and capecitabine, TNX induction chemotherapy, nedaplatin, N, docetaxel, cisplatin, and fluorouracil, TPF induction chemotherapy, cisplatin, P, docetaxel, cisplatin, and capecitabine, TPX induction chemotherapy, docetaxel, nedaplatin, and fluorouracil, TNF induction chemotherapy
Sun Yat-sen University, Tongji Hospital, Wuhan Union Hospital, China, Peking University, Air Force Military Medical University, China, Second Affiliated Hospital of Soochow University, The First Affiliated Hospital of Guangdong Pharmaceutical University, First People's Hospital of Foshan, Fifth Affiliated Hospital, Sun Yat-Sen University, Cancer Hospital of Guizhou Province, Xiangya Hospital of Central South University, Jilin Provincial Tumor Hospital, Henan Cancer Hospital, Hunan Cancer Hospital, Cancer Hospital of Guangxi Medical University, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Zhejiang Cancer Hospital
Nasopharyngeal Carcinoma
06/24
06/26
NCT05839899: Mifepristone and Misoprostol for Undesired Pregnancy of Unknown Location

Recruiting
3
50
US
Mifepristone plus one dose Misoprostol, Mifepristone plus two doses Misoprostol
Planned Parenthood League of Massachusetts
Abortion
07/24
09/24
HERTHENA-Lung02, NCT05338970 / 2021-005879-40: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy

Active, not recruiting
3
586
Europe, Canada, Japan, US, RoW
Patritumab Deruxtecan, HER3-DXd, U3-1402, Platinum-based chemotherapy
Daiichi Sankyo, Merck Sharp & Dohme LLC
Nonsquamous Non-small Cell Lung Cancer, EGFR L858R, EGFR Exon 19 Deletion
05/24
06/26
CYPRESS, NCT05696717: Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic NOH in Participants with Multiple System Atrophy

Recruiting
3
102
Europe, Canada, US, RoW
Ampreloxetine, TD-9855, Placebo
Theravance Biopharma
Symptomatic Neurogenic Orthostatic Hypotension, MSA - Multiple System Atrophy
12/24
01/27
NCT06672016: Study to Evaluate Contraceptive Efficacy and Safety of a Progestin Only Patch in Women of Childbearing Potential

Not yet recruiting
3
1500
US
Transdermal system containing progestin
Mylan Pharmaceuticals Inc
Female Contraception
03/27
04/27
VDJ001-RA-Ⅲ, NCT06726096: Phase III Trial of VDJ001 in Patients with Moderate-to-severe Active Rheumatoid Arthritis

Not yet recruiting
3
615
RoW
Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection
Beijing VDJBio Co., LTD.
Rheumatoid Arthritis (RA)
12/25
12/26
LIBERTY, NCT06716814: Study to Provide Continued Access to Treatment for Patients Completing a Previous Trial With Efanesoctocog Alfa

Not yet recruiting
3
78
Europe
Efanesoctocog alfa, BIVV001, Altuvoct, Altuviiio, Recombinant coagulation factor VIII Fc-von-Willebrand Factor-XTEN fusion protein (rFVIIIFc-VWF-XTEN)
Swedish Orphan Biovitrum, PSI CRO
Severe Haemophilia A
08/26
08/26
frontMIND, NCT04824092 / 2020-002990-84: Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients

Calendar Jul 2025 - Dec 2025: Primary analysis data from frontMIND trial in combination with Revlimid for newly diagnosed DLBCL
Hourglass Jun 2021 - Jun 2021 : Updated data from frontMIND trial for newly diagnosed DLBCL at EHA 2021
Hourglass Jun 2021 - Jun 2021 : Updated data from frontMIND trial for newly diagnosed DLBCL at ASCO 2021
Active, not recruiting
3
899
Europe, Canada, Japan, US, RoW
Tafasitamab, Monjuvi, Lenalidomide, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Tafasitamab placebo, Lenalidomide placebo
Incyte Corporation
Diffuse Large B-cell Lymphoma
06/25
05/26
StrataSTEPS, NCT05517902: StrataGraft Safety, Tolerability and Efficacy in Pediatric Subjects

Completed
3
1
US
StrataGraft
Stratatech, a Mallinckrodt Company, Biomedical Advanced Research and Development Authority
Skin Wound, Burns, Trauma-related Wound
05/24
05/24
DESTINY-Gastric04, NCT04704934 / 2020-004559-34: Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen

Jan 2024 - Dec 2024: Data from DESTINY-Gastric04 trial for HER2+ve gastric cancer
Jan 2024 - Dec 2024: Acceptance of regulatory submission for HER2 positive metastatic and/or unresectable gastric or gastroesophageal junction adenocarcinoma (based on DESTINY-Gastric04 trial)
Checkmark Data from DESTINY-Gastric04 trial for HER2 Positive Gastric Cancer (GC) or GEJ at ESMO 2021
Jul 2021 - Jul 2021: Data from DESTINY-Gastric04 trial for HER2 Positive Gastric Cancer (GC) or GEJ at ESMO 2021
Checkmark First patient was dosed in DESTINY-Gastric04 in patients with HER2 positive gastric or GEJ adenocarcinoma
More
Active, not recruiting
3
490
Europe, Japan, RoW
Trastuzumab deruxtecan, T-DXd, DS-8201a, ENHERTU®, Ramucirumab, CYRAMZA®, Paclitaxel
Daiichi Sankyo, AstraZeneca
Gastric Cancer, Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
10/25
02/26
NCT05847348: 68Ga-PSMA-11 Efficacy in Detecting BCR Prostate Cancer in Chinese Patients

Recruiting
3
110
RoW
68Ga-PSMA-11, Illucix, gallium Ga 68 Gozetotide, PET/CT or PET/MRI, Imaging by PET
Telix Pharmaceuticals (Innovations) Pty Limited, Grand Pharmaceutical (China) Co., Ltd.
Biochemical Recurrence of Malignant Neoplasm of Prostate, Prostate Cancer, BCR Prostate Carcinoma
12/25
07/26
DESTINY-Breast05, NCT04622319 / 2020-003982-20: A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy

Jan 2024 - Dec 2024: Acceptance of of regulatory submission for HER2+ post neo-adjuvant breast cancer (DESTINY-Breast05 trial)
Jan 2024 - Dec 2024: Data from DESTINY-Breast05 trial for HER2+ post neo-adjuvant breast cancer
Active, not recruiting
3
1600
Europe, Canada, Japan, US, RoW
DS-8201a, Trastuzumab deruxtecan (T-DXd), T-DM1, Trastuzumab emtansine (T-DM1)
Daiichi Sankyo, AstraZeneca, NSABP Foundation Inc, German Breast Group, Spanish Breast Cancer Research Group (SOLTI)
HER2-Positive Primary Breast Cancer, Residual Invasive Breast Cancer
12/25
12/30
FREEDOM, NCT05817812: A Study Evaluating Physical Activity and Joint Health in Severe Haemophilia A Patients ≥12 Years Treated Once Weekly With Efanesoctocog Alfa

Active, not recruiting
3
93
Europe, RoW
Efanesoctocog alfa, BIVV001
Swedish Orphan Biovitrum, Syneos Health
Hemophilia A, Severe
05/26
05/26
TROPION-Lung07, NCT05555732: Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer

Recruiting
3
1170
Europe, Canada, Japan, US, RoW
Datopotamab Deruxtecan, Dato-DXd, Pembrolizumab, KEYTRUDA®, Pemetrexed, Alimta, Pemfexy, Carboplatin, Cisplatin
Daiichi Sankyo, AstraZeneca, Merck Sharp & Dohme LLC
Metastatic Non Small Cell Lung Cancer
08/27
08/27
DESTINY-Breast15, NCT05950945: Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer

Recruiting
3
250
Europe, US, RoW
Trastuzumab Deruxtecan, T-DXd, DS-8201a (trastuzumab derextecan), Enhertu®
Daiichi Sankyo, AstraZeneca
Breast Cancer
10/27
10/27
Tropion-Lung08, NCT05215340 / 2021-002555-10: Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations

Jan 2024 - Dec 2024: Data from TROPION-Lung08 trial for advanced or metastatic NSCLC
Jan 2024 - Dec 2024: Acceptance of regulatory submission for 1L metastatic NSCLC (based on TROPION Lung08 trial)
Recruiting
3
740
Europe, Canada, Japan, US, RoW
Datopotamab Deruxtecan, Dato-DXd, Pembrolizumab, KEYTRUDA®
Daiichi Sankyo, AstraZeneca, Merck Sharp & Dohme LLC
Metastatic Non Small Cell Lung Cancer
02/28
04/28
ARTEMIS, NCT04797884: Electromagnetic Fields Versus Placebo For Child-Pugh A and B Patients With Advanced Hepatocellular Carcinoma

Recruiting
2/3
166
US
TheraBionic Device, Placebo Device, Quality of Life Assessment
THERABIONIC INC., National Cancer Institute (NCI)
Hepatocellular Carcinoma
10/24
10/24
FORTIFI-HN01, NCT06788990: a Study of Ficerafusp Alfa (BCA101) or Placebo in Combination with Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC

Recruiting
2/3
650
US
Ficerafusp alfa, Pembrolizumab (KEYTRUDA®), Placebo
Bicara Therapeutics
Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
04/28
07/29
TRIPHASE, NCT06101745: Trial to Visualize the Ureters With Nizaracianine Triflutate in Adults Undergoing Abdominopelvic Surgery

Recruiting
2/3
336
Europe
Nizaracianine Triflutate, ZW800-1, Placebo Comparator, Sugar
Curadel Surgical Innovations, Inc., Leiden University Medical Center, Erasmus Medical Center
Injury of Ureter During Surgery (Disorder)
10/25
11/25
ESTRELLA, NCT04764448 / 2020-003313-35: A Study of Belcesiran in Patients With AATLD

Terminated
2
16
Europe, Canada, US, RoW
Belcesiran, Placebo
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Alpha 1-Antitrypsin Deficiency
12/23
05/24
AAVIATE, NCT04514653: RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD)

Recruiting
2
115
US
Ranibizumab, RGX-314 Dose 1, Combination Product, RGX-314 Dose 2, RGX-314 Dose 3, Local Steroid, Topical Steroid
AbbVie, AbbVie
Neovascular Age-Related Macular Degeneration (nAMD)
10/25
08/26
RGX-314-2103, NCT04832724: RGX-314 Gene Therapy Pharmacodynamic Study for Neovascular Age-related Macular Degeneration (nAMD)

Completed
2
60
US
RGX-314
AbbVie
Neovascular Age-related Macular Degeneration, Wet Macular Degeneration, Wet Age-related Macular Degeneration
10/23
03/24
Orchid 1, NCT06132919: Efficacy and Safety of MC2-25 Cream & Vehicle in Women With Vulvar Lichen Sclerosus (VLS)

Recruiting
2
40
Europe
MC2-25 cream, MC2-25 vehicle
MC2 Therapeutics
Vulvar Lichen Sclerosus
11/24
11/24
StrataSOMA, NCT04765202: StrataGraft Overlay of Meshed Autograft in Full-thickness Thermal Burns

Completed
2
13
US
AG Tx, Meshed Autograft, SOMA Tx, StrataGraft skin tissue Overlay of Meshed Autograft (SOMA)
Stratatech, a Mallinckrodt Company
Full Thickness Thermal Burn
03/24
03/24
HERTHENA-PanTumor01, NCT06172478: A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

Recruiting
2
400
Europe, Japan, US, RoW
HER3-DXd, Patritumab Deruxtecan, U3-1402
Daiichi Sankyo, Merck Sharp & Dohme LLC
Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer, Ovarian Carcinoma, Cervical Cancer, Endometrial Cancer, Bladder Cancer, Esophageal Cancer, Pancreatic Carcinoma, Prostate Cancer
06/25
04/26
NCT05198310 / 2022-000169-42: Study to Assess the Safety, Pharmacokinetics, and Efficacy of KPL-404 in Participants With Rheumatoid Arthritis With Inadequate Response or Intolerance to at Least One Biologic Disease-modifying Anti-rheumatic Drug or a Janus Kinase Inhibitor

Completed
2
145
Europe, US, RoW
KPL-404, Placebo
Kiniksa Pharmaceuticals, Ltd., Kiniksa Pharmaceuticals, Ltd.
Arthritis, Rheumatoid
02/24
05/24
EAD501, NCT05607615 / 2022-003819-29: A 6-Month Study to Evaluate the Safety & Potential Efficacy of Trappsol Cyclo in Patients With Early Alzheimer's Disease

Recruiting
2
90
US
Hydroxypropyl Beta Cyclodextrin, Trappsol Cyclo, Placebo, 0.5N saline
Cyclo Therapeutics, Inc., Cyclo Therapeutics Inc.
Alzheimer's Disease
03/24
03/24
NCT05569252 / 2022-000676-19: A Study of DS-1211b in Individuals With PseudoXanthoma Elasticum

Completed
2
65
Europe, US
DS-1211b, Placebo
Daiichi Sankyo, PXE International
Pseudoxanthoma Elasticum
11/23
11/23
IDeate-PanTumor02, NCT06330064: A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors

Recruiting
2
520
Europe, Japan, US, RoW
Ifinatamab deruxtecan, I-DXd
Daiichi Sankyo, Merck Sharp & Dohme LLC
Recurrent or Metastatic Solid Tumors
07/28
07/28
MAST, NCT06355583: Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant () Trial

Not yet recruiting
2
50
Europe
EBX-102, IMT capsules, Placebo
Imperial College London
Acute Lymphoblastic Leukaemia, Acute Leukemia of Ambiguous Lineage, Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Acute Myeloid Leukemia
02/26
05/27
NCT04870905: Tisleilizumab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma

Not yet recruiting
2
100
RoW
Tis-U-Sol
Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Union hospital of Fujian Medical University, Zhujiang Hospital, Guangdong Provincial People's Hospital
Nasopharyngeal Neoplasms
05/24
05/26
IDeate-Lung01, NCT05280470 / 2022-000503-13: Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

Active, not recruiting
2
187
Europe, Japan, US, RoW
Ifinatamab Deruxtecan (I-DXd), DS-7300a
Daiichi Sankyo, Merck Sharp & Dohme LLC
Extensive-stage Small-cell Lung Cancer
01/25
04/25
SPG302-SCZ-201, NCT06442462: Study of SPG302 in Adults With Schizophrenia

Recruiting
2
32
RoW
SPG302, Placebo
Spinogenix
Schizophrenia
06/25
10/25
CBeyond, NCT06577090: Study to Evaluate the Effect on Obesity of Once Weekly Nimacimab Injection and Once Weekly Nimacimab Injection Co-administered With Semaglutide Injection Versus Placebo

Recruiting
2
120
US
Nimacimab injection, Nimacimab placebo injection, semaglutide injection
Skye Bioscience, Inc., Bird Rock Bio Sub, Inc.
Obesity
08/25
01/26
NCT05029336: Autologous Stem Cell Transplant (ASCT) for Autoimmune Diseases

Recruiting
2
20
US
Depletion of CD3/CD19 in an autologous stem cell transplant, CD3/CD19 depletion using cliniMACs device
Stephan Grupp MD PhD
Systemic Lupus Erythematosus, Systemic Sclerosis
12/26
05/31
ALM-488-004, NCT06662097: A Study of Bevonescein in Patients Undergoing Abdominopelvic Surgery

Recruiting
2
64
US
Bevonescein, ALM-488
Alume Biosciences, Inc.
Surgery, Nerve Injury, Imaging
06/25
09/25
NCT04935762: A Study of CST-103 Co-administered With CST-107 in Subjects With Parkinson's Disease Having Freezing of Gait (CLIN-012)

Withdrawn
2
25
RoW
CST-103, CST-107, matching placebo
CuraSen Therapeutics, Inc.
Freezing of Gait Symptoms in Parkinson's Disease
12/24
03/25
REJOICE-PanTumor01, NCT06660654: A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors

Not yet recruiting
2
200
Japan, US
Raludotatug deruxtecan, R-DXd
Daiichi Sankyo, Merck Sharp & Dohme LLC
Advanced Solid Tumor, Metastatic Solid Tumors
09/27
09/27
NCT04977024: SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer

Recruiting
2
240
US
COVID-19 Vaccine, Diagnostic Laboratory Biomarker Analysis, Synthetic MVA-based SARS-CoV-2 Vaccine GEO-CM04S1, COH04S1, SARS-CoV-2 Vaccine COH04S1, sMVA-based SARS-CoV-2 Vaccine COH04S1, GEO-CM04S1
GeoVax, Inc., National Cancer Institute (NCI)
COVID-19 Infection, Hematopoietic and Lymphoid System Neoplasm, Leukemia, Lymphoma, Plasma Cell Myeloma
12/26
12/27
STEP, NCT06594393: A Phase 2 Study of TCP-25 Gel in Patients with Epidermolysis Bullosa, -study

Not yet recruiting
2
26
Europe
TCP-25 gel, Vehicle (placebo)
Xinnate AB
Epidermolysis Bullosa (EB)
06/26
06/26
NCT06038578: A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer

Recruiting
2
146
Japan, US, RoW
TRK-950, Ramucirumab, CYRAMZA®, Paclitaxel
Toray Industries, Inc
Gastric Adenocarcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
08/25
08/25
NCT05205330 / 2020-002435-29: CR6086/AGEN2034 Combination in Stage IV pMMR - MSS CRC, and Other Metastatic GI Cancers

Recruiting
1/2
55
Europe
CR6086, vorbipiprant, AGEN2034, balstilimab
Rottapharm Biotech, Agenus Inc.
Refractory Metastatic Colorectal Cancer, Solid Tumor, Metastatic Microsatellite-stable Colorectal Cancer, Mismatch Repair Protein Proficient, Metastatic GI Cancers, Gastric Cancer
03/25
09/26
NCT05638802: A Study of DS-7011a in Patients With Systemic Lupus Erythematosus

Active, not recruiting
1/2
26
US
DS-7011a, Placebo
Daiichi Sankyo
Systemic Lupus Erythematosus
04/25
04/25
NCT03520075 / 2018-004568-72: Study of ASTX029 in Subjects With Advanced Solid Tumors

Active, not recruiting
1/2
190
Europe, US
ASTX029
Taiho Oncology, Inc.
Solid Tumor, Adult
08/24
12/25
NCT05979831: A Study to Explore Safety, Pharmacokinetics, and Early Clinical Signal of Efficacy of DS-2325a in Patients With Netherton Syndrome

Active, not recruiting
1/2
9
Europe
DS-2325a, Placebo
Daiichi Sankyo
Netherton Syndrome
01/25
01/25
 

Download Options